HUE055020T2 - Prosztata-antigén szabványok és azok felhasználása - Google Patents

Prosztata-antigén szabványok és azok felhasználása

Info

Publication number
HUE055020T2
HUE055020T2 HUE16773820A HUE16773820A HUE055020T2 HU E055020 T2 HUE055020 T2 HU E055020T2 HU E16773820 A HUE16773820 A HU E16773820A HU E16773820 A HUE16773820 A HU E16773820A HU E055020 T2 HUE055020 T2 HU E055020T2
Authority
HU
Hungary
Prior art keywords
prostate antigen
antigen standards
standards
prostate
antigen
Prior art date
Application number
HUE16773820A
Other languages
English (en)
Inventor
Vincent Linder
Christina Higgins
Original Assignee
Opko Diagnostics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Diagnostics Llc filed Critical Opko Diagnostics Llc
Publication of HUE055020T2 publication Critical patent/HUE055020T2/hu

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
HUE16773820A 2015-03-27 2016-03-25 Prosztata-antigén szabványok és azok felhasználása HUE055020T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562139365P 2015-03-27 2015-03-27

Publications (1)

Publication Number Publication Date
HUE055020T2 true HUE055020T2 (hu) 2021-11-29

Family

ID=56975150

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16773820A HUE055020T2 (hu) 2015-03-27 2016-03-25 Prosztata-antigén szabványok és azok felhasználása

Country Status (16)

Country Link
US (1) US11921115B2 (hu)
EP (2) EP3253800B1 (hu)
JP (1) JP6749337B2 (hu)
CN (1) CN107406510B (hu)
CA (1) CA2979559A1 (hu)
DE (1) DE202016008692U1 (hu)
DK (1) DK3253800T3 (hu)
ES (1) ES2867798T3 (hu)
HU (1) HUE055020T2 (hu)
IL (1) IL254412B (hu)
MX (2) MX2017012320A (hu)
PL (1) PL3253800T3 (hu)
PT (1) PT3253800T (hu)
TW (1) TWI698639B (hu)
UA (1) UA124522C2 (hu)
WO (1) WO2016160545A1 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2687620T3 (es) 2007-05-04 2018-10-26 Opko Diagnostics, Llc Dispositivo y método para análisis en sistemas microfluídicos
EP2391451B1 (en) 2009-02-02 2018-09-12 Opko Diagnostics, LLC Structures for controlling light interaction with microfluidic devices
TWI638277B (zh) 2012-03-05 2018-10-11 Ｏｐｋｏ診斷法有限責任公司 用於確定前列腺癌相關事件之機率之分析系統及方法
MX2016012667A (es) 2014-03-28 2017-01-09 Opko Diagnostics Llc Composiciones y metodos relacionados con el diagnostico de cancer de prostata.
DE102015105979A1 (de) 2015-04-20 2016-10-20 Mankiewicz Gebr. & Co. Gmbh & Co. Kg Verbesserte Beschichtungssysteme, deren Verwendung zur Beschichtung von Bauteilen sowie damit beschichtete Bauteile für Windkraftanlagen
WO2017100457A1 (en) 2015-12-11 2017-06-15 Opko Diagnostics, Llc Fluidic systems involving incubation samples and/or reagents
JP6956719B2 (ja) 2015-12-29 2021-11-02 オプコ・ダイアグノスティクス・リミテッド・ライアビリティ・カンパニーＯｐｋｏ Ｄｉａｇｎｏｓｔｉｃｓ，Ｌｌｃ 流体の収集のための物品
EP3639031A4 (en) * 2017-06-15 2021-05-05 Sunstone Scientific Limited. METHOD OF IHC ANTIGEN IMAGE SCALE EXTRAPOLATION
US11662564B2 (en) 2017-06-15 2023-05-30 Shenzhen Prs Limited Paraffin shield coating for microscope slide

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
EP0635575A1 (en) 1993-07-22 1995-01-25 Wallac Oy Monoclonal antibodies against epitopes found in free but not in alpha-1-antichmotrypsin complexed prostate specific antigen
US5516639A (en) 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
ATE263962T1 (de) 1993-10-28 2004-04-15 I Stat Corp Vorrichtung zur abnahme und einleitung von flüssigkeitsproben
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5585069A (en) 1994-11-10 1996-12-17 David Sarnoff Research Center, Inc. Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis
US5614372A (en) 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
CA2228485A1 (en) 1995-08-03 1997-02-20 Akzo Nobel Nv Diagnostic device
US6143509A (en) 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
WO1997039351A1 (en) 1996-04-12 1997-10-23 Carter Herbert B Novel methods for the prediction and early detection of prostatic adenocarcinoma
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
US5945289A (en) 1996-12-20 1999-08-31 Lehrer; Steven Method for detecting prostate cancer by apolipoprotein E (Apo-E) genotyping
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
SE9704934D0 (sv) 1997-12-30 1997-12-30 Pharmacia & Upjohn Diag Ab Analysförfarande med tillsättning i två eller flera positioner
FI980488A (fi) 1998-03-04 1999-09-05 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
FR2780791B1 (fr) 1998-07-03 2000-09-01 Bio Merieux Methode de depistage ou de diagnostic d'un adenocarcinome ou d'une pathologie benigne de la prostate et procede de mise en oeuvre
WO2000044940A2 (en) 1999-01-28 2000-08-03 Gen-Probe Incorporated Nucleic acid sequences for detecting genetic markers for cancer in a biological sample
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US7211397B2 (en) 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
US6136549A (en) 1999-10-15 2000-10-24 Feistel; Christopher C. systems and methods for performing magnetic chromatography assays
FI20002127A0 (fi) 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
WO2002030562A1 (en) 2000-10-10 2002-04-18 Aviva Biosciences Corporation An integrated biochip system for sample preparation and analysis
JP2004536278A (ja) 2000-11-20 2004-12-02 イースタン・ヴァージニア・メディカル・スクール 前立腺特異的膜抗原、その他の前立腺マーカーの定量的検出方法及び装置
US20040219163A1 (en) 2001-10-03 2004-11-04 Frelinger John G. Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
US7258837B2 (en) 2001-12-05 2007-08-21 University Of Washington Microfluidic device and surface decoration process for solid phase affinity binding assays
US20030235816A1 (en) 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
US20050272052A1 (en) 2002-04-09 2005-12-08 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
JPWO2003100425A1 (ja) 2002-05-28 2005-11-04 株式会社常光 免疫学的クロマトグラフ法の試験紙片の読み取り定量装置
NZ562192A (en) 2002-08-06 2009-07-31 Ciphergen Biosystems Inc Use of biomarkers for detecting ovarian cancer
US20040115794A1 (en) 2002-12-12 2004-06-17 Affymetrix, Inc. Methods for detecting transcriptional factor binding sites
WO2004070056A2 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
US7461048B2 (en) 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US20060269971A1 (en) 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer
EP1535667A1 (en) 2003-11-28 2005-06-01 Sysmex Corporation Analyzer, assay cartridge and analyzing method
EP1691924B1 (en) 2003-12-10 2016-09-14 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin A modular biochip assembly
EP1704405A1 (en) 2003-12-31 2006-09-27 The President and Fellows of Harvard College Assay device and method
CN102357352B (zh) 2004-01-26 2015-08-12 哈佛大学 流体递送系统和方法
US8030057B2 (en) 2004-01-26 2011-10-04 President And Fellows Of Harvard College Fluid delivery system and method
TW200538734A (en) 2004-03-12 2005-12-01 Aureon Biosciences Corp Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
EP1747466A2 (en) 2004-05-11 2007-01-31 Baylor College Of Medicine Method to predict prostate cancer
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
WO2006022895A2 (en) 2004-08-02 2006-03-02 Children's Medical Center Corporation Platelet biomarkers for cancer
WO2006034032A2 (en) 2004-09-17 2006-03-30 The Johns Hopkins University Biomarkers for breast cancer
US8663600B2 (en) 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
WO2006122312A2 (en) 2005-05-11 2006-11-16 The Trustees Of The University Of Pennsylvania Methods of testing using a microfluidic cassette
US20070065954A1 (en) 2005-09-15 2007-03-22 Minoru Taya Surface plasmon resonance biosensor system for detection of antigens and method for determining the presence of antigens
CN101454331A (zh) 2006-03-24 2009-06-10 菲诺梅诺米发现公司 有效用于诊断前列腺癌的生物标记，及其方法
CA2656140A1 (en) 2006-07-03 2008-01-10 Exonhit Therapeutics Sa Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
CN1973778A (zh) 2006-12-08 2007-06-06 南京大学 胃癌术后严重并发症风险度的预测方法
RU2502074C2 (ru) 2006-12-22 2013-12-20 Фадиа Аб Новый аллерген-простатический калликреин
ES2687620T3 (es) 2007-05-04 2018-10-26 Opko Diagnostics, Llc Dispositivo y método para análisis en sistemas microfluídicos
JP2010528261A (ja) 2007-05-08 2010-08-19 ピコベラ・リミテッド・ライアビリティ・カンパニー 前立腺癌および肺癌の診断および治療方法
CN101329343A (zh) 2007-06-19 2008-12-24 天津迪爱盟生物技术有限公司 新一代早期诊断前列腺癌试剂盒及其制备方法和检测方法
US20090087860A1 (en) 2007-08-24 2009-04-02 Todd John A Highly sensitive system and methods for analysis of prostate specific antigen (psa)
CN101377500A (zh) 2007-08-31 2009-03-04 北京科美东雅生物技术有限公司 游离前列腺特异性抗原化学发光免疫分析测定试剂盒及其制备方法
EP2208072B1 (en) 2007-10-22 2015-07-01 St Vincent's Hospital Sydney Limited Methods of prognosis
WO2009085196A1 (en) 2007-12-21 2009-07-09 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
JP5028697B2 (ja) 2008-02-18 2012-09-19 富士フイルム株式会社 吸引シリンジ及び内視鏡用吸引シリンジ
CA2724433A1 (en) 2008-05-14 2009-11-19 Eth Zuerich Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
FR2934698B1 (fr) 2008-08-01 2011-11-18 Commissariat Energie Atomique Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede.
WO2010047767A2 (en) 2008-10-20 2010-04-29 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same
CA2745961A1 (en) 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
EP2376226B1 (en) 2008-12-18 2018-09-12 Opko Diagnostics, LLC Improved reagent storage in microfluidic systems and related articles and methods
WO2010075446A1 (en) 2008-12-23 2010-07-01 Soar Biodynamics, Ltd. Methods and systems for prostate health monitoring
US20120022793A1 (en) 2009-01-19 2012-01-26 Miraculins, Inc. Biomarkers for the diagnosis of prostate cancer in a non-hypertensive population
EP2391451B1 (en) 2009-02-02 2018-09-12 Opko Diagnostics, LLC Structures for controlling light interaction with microfluidic devices
JP2010243406A (ja) 2009-04-08 2010-10-28 F Hoffmann La Roche Ag Ａｆｐおよびｐｉｖｋａ−ｉｉの測定値を特徴値とした識別関数を利用する、肝臓癌および慢性肝疾患の病態進行度の検出方法
CA2760333A1 (en) 2009-05-01 2010-11-04 Genomic Health Inc. Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
CN102483416A (zh) 2009-06-04 2012-05-30 梅坦诺米克斯保健有限公司 诊断前列腺癌的工具和方法
WO2011027308A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
WO2011027310A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
KR101141190B1 (ko) 2009-10-19 2012-06-13 중앙대학교 산학협력단 전립선암에 대한 바이오마커 및 이를 이용한 전립선암 진단
JP5932670B2 (ja) 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
CN102939160B (zh) 2010-04-16 2016-10-12 欧普科诊断有限责任公司 用于样本分析的系统和装置
WO2012029080A1 (en) 2010-08-30 2012-03-08 Decode Genetics Ehf Sequence variants associated with prostate specific antigen levels
BRPI1100857A2 (pt) 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
US9594086B2 (en) 2011-03-22 2017-03-14 The Johns Hopkins University Biomarkers for aggressive prostate cancer
WO2012170776A2 (en) * 2011-06-09 2012-12-13 Quanterix Corporation Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
WO2013012028A1 (ja) 2011-07-21 2013-01-24 和光純薬工業株式会社 血漿中アミノ酸分析用標準液
MX353964B (es) 2011-10-28 2018-02-06 Fredax Ab Agentes terapeuticos y usos de los mismos.
US20150044666A1 (en) 2012-01-13 2015-02-12 Iris International Inc. Non-equilibrium two-site assays for linear, ultrasensitive analyte detection
TWI638277B (zh) 2012-03-05 2018-10-11 Ｏｐｋｏ診斷法有限責任公司 用於確定前列腺癌相關事件之機率之分析系統及方法
AU2013263473A1 (en) 2012-05-16 2014-11-20 Phadia Ab Method for indicating the presence or non-presence of prostate cancer
BR112014032728A2 (pt) 2012-06-27 2017-11-28 Berg Llc uso de marcadores no diagnóstico e tratamento de câncer de próstata
CN102818892B (zh) 2012-08-16 2015-02-18 北京恩济和生物科技有限公司 一种前列腺特异性抗原检测试剂盒及其制备方法
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
ES2694409T3 (es) 2012-11-20 2018-12-20 Phadia Ab Método de pronóstico para individuos con cáncer de próstata
AU2013349801B2 (en) 2012-11-20 2019-03-07 Phadia Ab Method for indicating a presence or non-presence of aggressive prostate cancer
MX2016006561A (es) 2013-11-19 2016-12-12 Fredax Ab Anticuerpo anti-calicreina-2 humanizado.
JP6625061B2 (ja) 2014-03-11 2019-12-25 ファディア・アクチボラゲットＰｈａｄｉａ ＡＢ 固形腫瘍癌を検出する方法
US20170089904A1 (en) 2014-03-28 2017-03-30 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
MX2016012667A (es) 2014-03-28 2017-01-09 Opko Diagnostics Llc Composiciones y metodos relacionados con el diagnostico de cancer de prostata.
US10217619B2 (en) 2015-03-12 2019-02-26 Thermo Finnigan Llc Methods for data-dependent mass spectrometry of mixed intact protein analytes
WO2016176529A1 (en) 2015-04-29 2016-11-03 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
US20190072555A1 (en) 2017-08-14 2019-03-07 Opko Diagnostics, Llc Multiplex assays for evaluating prostate cancer status
WO2019221930A1 (en) 2018-05-16 2019-11-21 Opko Diagnostics, Llc Methods for detecting prostate cancer pathology associated with adverse outcomes

Also Published As

Publication number Publication date
EP3318878A3 (en) 2018-07-11
EP3253800A1 (en) 2017-12-13
DE202016008692U1 (de) 2019-02-13
CN107406510A (zh) 2017-11-28
UA124522C2 (uk) 2021-10-05
DK3253800T3 (da) 2021-05-31
EP3318878A2 (en) 2018-05-09
EP3253800B1 (en) 2021-03-03
TW201643429A (zh) 2016-12-16
US20160282349A1 (en) 2016-09-29
CN107406510B (zh) 2022-02-18
JP6749337B2 (ja) 2020-09-02
IL254412B (en) 2021-01-31
JP2018511055A (ja) 2018-04-19
US11921115B2 (en) 2024-03-05
WO2016160545A1 (en) 2016-10-06
MX2022002138A (es) 2022-03-17
US20170370938A9 (en) 2017-12-28
TWI698639B (zh) 2020-07-11
EP3253800A4 (en) 2018-11-07
PL3253800T3 (pl) 2021-08-23
CA2979559A1 (en) 2016-10-06
MX2017012320A (es) 2018-01-18
IL254412A0 (en) 2017-11-30
ES2867798T3 (es) 2021-10-20
PT3253800T (pt) 2021-04-28

Similar Documents

Publication Publication Date Title
IL285375A (en) Antibodies that bind to il-8 and their uses
IL283321A (en) Antibodies against muc16 and their uses
HK1254861A1 (zh) 抗lag3抗體及其用途
HK1250238A1 (zh) 抗angptl8抗體及其用途
HK1255067A1 (zh) 抗c10orf54抗體及其用途
HK1243440A1 (zh) 抗白細胞介素-33抗體及其用途
IL247407B (en) Antibodies against egfrviii and their uses
HK1256381A1 (zh) 抗pacap抗體及其用途
IL254412A0 (en) Prostate antigen standard and its uses
GB201503387D0 (en) Anti-carbapenem antibodies and uses thereof
IL251001B (en) Anti-il-25 antibodies and their uses
RS62912B1 (sr) Antihumana-her3 antitela i njihova primena
HK1254240A1 (zh) 抗羥腐胺賴氨酸抗體及其用途
HK1247934A1 (zh) Aml抗原及其用途